Clinical Trial Update: Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of Vicriviroc in combination with pembrolizumab in advanced/metastatic microsatellite-stable colorectal cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Vicriviroc (MK-7690)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-06-07